Germline BRCA1 and BRCA2 mutations have been identified in 14–15% of all ovarian cancers while somatic BRCA1 and BRCA2 mutations are found in 6–7% of high grade serous EOCs [39]. This evidence concerns the gene BRCA2 and ovarian carcinoma.